.
-as of [3 MARCH 2024]–
.
.
(formerly ‘crucell’)
.
-‘janssen vaccines’ is a ‘bio-technology company’ specializing in ‘vaccines’ + ‘bio-pharmaceutical technologies’-
.
It was formed when Johnson & Johnson acquired the Dutch biotech company Crucell based in Leiden and placed it in their pharmaceutical division
.
History
In 1993 ‘Introgene’, Crucell’s predecessor, was established as a spin-off of Leiden University.
The company formed a partnership with Genzyme to collaborate on its vector technology and viral-based products. In 1999 the company founded Galapagos Genomics as a joint venture together with Tibotec. In 2000 IntroGene acquired U-Bisys to form Crucell.
In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.
On 7 January 2009 Crucell released a press release saying Crucell and Wyeth were in discussion on a merger of the two companies. On 26 January 2009 Crucell released another press release saying the discussions on a combination of Crucell and Wyeth was discontinued due to Pfizer’s acquisition of Wyeth.
In September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 million in order to collaborate on the development of a flu vaccine.[1] This followed Crucell’s discovery of CR6261, a potent human antibody that neutralizes a broad range of influenza A viruses. J&J acquired the rest of the company in October 2010, taking its stake to over 95% by February 2011[2][3] and delisting the company from stock exchanges two months later.[4]
After the takeover by Johnson & Johnson in 2011, Crucell was assigned to Janssen Pharmaceuticals division. In 2014, the subsidiary was renamed from Crucell to Janssen Vaccines.[5][6]
COVID-19 vaccine development[edit]
Janssen Vaccines in Leiden developed the COVID-19 vaccines for Johnson & Johnson. Initial production of the vaccine is happening at Janssen Biotech in Leiden, Netherlands. The vaccine stands out because it is the first single-shot vaccine against COVID-19 that was developed during the COVID-19 pandemic.
References[edit]
^ Gray-Block, Aaron (28 September 2009). “Johnson & Johnson buys 18 pct stake in Crucell”. Reuters. Retrieved 28 September 2009.
^ Solsman, Joan E. (17 February 2011). “J&J: Sufficient Number Of Crucell Holders Tender Shares”. The Wall Street Journal. Dow Jones Newswires. Retrieved 27 February 2011.
^ “J&J aiming to buy vaccine maker Crucell for $2.3 billion”. Reuters. 17 September 2010.
^ Gray-Block, Aaron (11 April 2011). “Crucell to be delisted after J&J buyout”. Reuters. Retrieved 16 April 2011.
^ “Crucell”. DevEx. 2015.
^ “Janssen Vaccines AG”. Company Profiles. Bloomberg. 2020.
en.wikipedia.org /wiki/Janssen_Vaccines
Janssen Vaccines
Contributors to Wikimedia projects3-4 minutes 10/25/2006
Coordinates: 52°09′56″N 4°28′02″E / 52.1655°N 4.4673°E
Janssen Vaccines
Janssen Pharmaceuticals logo.svg
Archimedesweg 4 Leiden.jpg
Type Privately held naamloze vennootschap; subsidiary
Industry Biotechnology
Founded 2000
Headquarters Archimedesweg 4,
Leiden
,
Netherlands
.
Key people
Ronald Brus (CEO), Jan Pieter Oosterveld (Chairman of the supervisory board)
Products Vaccines and antibodies
Owner Johnson & Johnson
Website www.janssen.com
Edit this on Wikidata
.
.
*👨🔬🕵️♀️🙇♀️*SKETCHES*🙇♂️👩🔬🕵️♂️*
.
.
.
.
.
💕💝💖💓🖤💙🖤💙🖤💙🖤❤️💚💛🧡❣️💞💔💘❣️🧡💛💚❤️🖤💜🖤💙🖤💙🖤💗💖💝💘
.
.
*🌈✨ *TABLE OF CONTENTS* ✨🌷*
.
.
🔥🔥🔥🔥🔥🔥*we won the war* 🔥🔥🔥🔥🔥🔥